Literature DB >> 2987017

Actions of kynurenic acid and quinolinic acid in the rat hippocampus in vivo.

M N Perkins, T W Stone.   

Abstract

An iontophoretic study was made of the interaction of kynurenic acid with excitatory amino acids in the hippocampus and with the commissural input from the contralateral hippocampus in the rat. The results showed that kynurenic acid was an effective blocker of synaptic transmission in the hippocampus in vivo, adding further support to the idea that an excitatory amino acid is involved in neurotransmission in this structure. In addition there was an increase in the specificity of kynurenate as an antagonist of excitatory amino acids in the hippocampus compared with neocortex, with much more activity being shown toward the NMDA-preferring rather than the quisqualic acid-preferring receptor. Kynurenic acid was also able to distinguish partially between quinolinic acid and NMDA, supporting the possibility that two types of NMDA/quinolinate receptors exist in the hippocampus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987017     DOI: 10.1016/0014-4886(85)90072-x

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  12 in total

1.  The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia.

Authors:  Martina Ulivieri; Joanna Monika Wierońska; Luana Lionetto; Katiuscia Martinello; Paulina Cieslik; Agnieszka Chocyk; Martina Curto; Luisa Di Menna; Luisa Iacovelli; Anna Traficante; Francesca Liberatore; Giada Mascio; Nico Antenucci; Giuseppe Giannino; Matteo Vergassola; Anna Pittaluga; Valeria Bruno; Giuseppe Battaglia; Sergio Fucile; Maurizio Simmaco; Ferdinando Nicoletti; Andrzej Pilc; Francesco Fazio
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

2.  New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio.

Authors:  Tomasz Kocki; Sebastian Wnuk; Renata Kloc; Janusz Kocki; Björn Owe-Larsson; Ewa M Urbanska
Journal:  J Neural Transm (Vienna)       Date:  2011-06-10       Impact factor: 3.575

Review 3.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

4.  A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.

Authors:  P Winn; T W Stone; M Latimer; M H Hastings; A J Clark
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

5.  A quantitative pharmacological analysis of some excitatory amino acid receptors in the mouse neocortex in vitro.

Authors:  N R Burton; D A Smith; T W Stone
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

6.  Actions of excitatory amino acid antagonists on geniculo-cortical transmission in the cat's visual cortex.

Authors:  K Hagihara; T Tsumoto; H Sato; Y Hata
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

7.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.

Authors:  Nicholas W S Davies; Gilles Guillemin; Bruce J Brew
Journal:  Int J Tryptophan Res       Date:  2010-06-10

Review 8.  Changing the face of kynurenines and neurotoxicity: therapeutic considerations.

Authors:  Zsuzsanna Bohár; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  Int J Mol Sci       Date:  2015-04-29       Impact factor: 5.923

Review 9.  Kynurenines in CNS disease: regulation by inflammatory cytokines.

Authors:  Brian M Campbell; Erik Charych; Anna W Lee; Thomas Möller
Journal:  Front Neurosci       Date:  2014-02-06       Impact factor: 4.677

Review 10.  Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.

Authors:  Zsófia Majláth; Nóra Török; József Toldi; László Vécsei
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.